Saneca Pharma strengthens senior team
Jeremy Drummond will focus on growing the CDMO’s API and finished dosage form development and manufacturing business in Europe and North America.
Slovakia-based CDMO, Saneca Pharma, has added senior talent to its team to position the company for its next phase of growth.
With a background in the pharmaceutical contract services industry spanning over 20 years, Jeremy Drummond joins the CDMO as sales and marketing director.
Jeremy will be focused on growing Saneca Pharma’s API and finished dosage form development and manufacturing business in Europe and North America.
Juraj Kubáň also joins the CDMO in the role of project development manager. With a background in pharmaceutical project management and a PhD in organic chemistry, Juraj will assist Saneca Pharma’s customers with the efficient transfer of products from API through to finished dosage form.
Anthony Sheehan, CEO at Saneca Pharma said: “Our site has a strong big pharma heritage, with over 70 years’ expertise in producing APIs and finished dosage forms. Following the company’s transition to CDMO, a key focus is to ensure the market and customers understand what makes the Saneca Pharma offering different.
“Adding the likes of Jeremy and Juraj to our senior management team underlines our commitment to be the outsourcing partner of choice for pharmaceutical companies in need of a technically agile and responsive CDMO. Both have exceptional experience in the contract services sector that will help ensure we compete with the biggest CMOs and CDMOs across the globe.”
From its site in Hlohovec, Slovakia, Saneca Pharma provides full service development and manufacturing capabilities for APIs and finished dosage forms. With particular expertise in controlled substances, the CDMO can produce opiate products from ‘farm to pharmacy’, simplifying the supply chain for its customers.
Jeremy said: “As the biggest pharmaceutical company in Slovakia with significant growth plans for the contract manufacturing business, it’s an exciting time to join Saneca. We are well positioned to offer a fully integrated drug development, manufacturing and supply service thanks to the range of technologies and quality of pharmaceutical expertise found on our site.
“We expect to experience steady growth in the coming months as our team has the technical agility to handle multi-step products, complex molecules, novel release mechanisms and patient compliance challenges; services that are in demand in today’s market.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance